CD44 alternative splicing is a sensor of intragenic DNA methylation in tumors
DNA methylation (meDNA) is a suspected modulator of alternative splicing, while splicing in turn is involved in tumour formations nearly as frequently as DNA mutations. Yet, the impact of meDNA on tumorigenesis via its effect on splicing has not been thoroughly explored. Here, we find that HCT116 colon carcinoma cells inactivated for the DNA methylases DNMT1 and DNMT3b undergo a partial epithelial to mesenchymal transition (EMT) associated with alternative splicing of the CD44 transmembrane receptor. The skipping of CD44 variant exons is in part explained by altered expression or splicing of splicing and chromatin factors. A direct effect of meDNA on alternative splicing was sustained by transient depletion of DNMT1 and the methyl-binding genes MBD1, MBD2, and MBD3. Yet, local changes in intragenic meDNA also altered recruitment of MBD1 protein and of the chromatin factor HP1$\gamma$ known to alter transcriptional pausing and alternative splicing decisions. We further tested if meDNA level has sufficiently strong direct impact on the outcome of alternative splicing to have a predictive value in the MCF10A model for breast cancer progression and in patients with acute lymphoblastic leukemia (B ALL). We found that a small number of differentially spliced genes mostly involved in splicing and signal transduction is systematically correlated with local meDNA. Altogether, our observations suggest that, although DNA methylation has multiple avenues to alternative splicing, its indirect effect may be also mediated through alternative splicing isoforms of these sensors of meDNA.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Decoding Dmrt1: Insights into vertebrate sex determination and gonadal sex differentiation
Dmrt1 is pivotal in testis formation and function by interacting with genes crucial for Sertoli cell differentiation. Dmrt1, or Sox9, forms a conserved antagonistic interaction with Foxl2 across mammals. Across 128 verte…
Artificial Intelligence Solution for Effective Treatment Planning for Glioblastoma Patients
Glioblastomas are the most common malignant brain tumors in adults. Approximately 200000 people die each year from Glioblastoma in the world. Glioblastoma patients have a median survival of 12 months with optimal therapy…
Brain Tumor SegmentationSegmentationTumor SegmentationDecoding MGMT Methylation: A Step Towards Precision Medicine in Glioblastoma
Glioblastomas, constituting over 50% of malignant brain tumors, are highly aggressive brain tumors that pose substantial treatment challenges due to their rapid progression and resistance to standard therapies. The methy…
RNA Alternative Splicing Prediction with Discrete Compositional Energy Network
A single gene can encode for different protein versions through a process called alternative splicing. Since proteins play major roles in cellular functions, aberrant splicing profiles can result in a variety of diseases…
MGMT promoter methylation status prediction using MRI scans? An extensive experimental evaluation of deep learning models
The number of studies on deep learning for medical diagnosis is expanding, and these systems are often claimed to outperform clinicians. However, only a few systems have shown medical efficacy. From this perspective, we …
Deep LearningMedical Diagnosis